Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2023-01-01 DOI:10.2147/BCTT.S395054
Selman Emiroglu, Enver Özkurt, Neslihan Cabıoglu, Abdullah Igci, Pinar Saip, Hulya Yazici, Tolga Ozmen, Vahit Ozmen, Mahmut Muslumanoglu, Mustafa Tukenmez
{"title":"Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation?","authors":"Selman Emiroglu,&nbsp;Enver Özkurt,&nbsp;Neslihan Cabıoglu,&nbsp;Abdullah Igci,&nbsp;Pinar Saip,&nbsp;Hulya Yazici,&nbsp;Tolga Ozmen,&nbsp;Vahit Ozmen,&nbsp;Mahmut Muslumanoglu,&nbsp;Mustafa Tukenmez","doi":"10.2147/BCTT.S395054","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The optimal surgical therapy for newly diagnosed breast cancer with germline mutations in susceptibility genes is still uncertain for many physicians. In this study, we aimed to determine the efficacy of breast conserving surgery (BCS) in breast cancer patients with <i>BRCA1</i> or <i>BRCA2</i> mutation by assessing its outcomes and locoregional recurrence (LR) rates.</p><p><strong>Materials and methods: </strong>Seventy-five patients operated with BCS or mastectomy for breast cancer between 2006 and 2017 and had <i>BRCA1</i> or <i>BRCA2</i> mutation were included in the study. Effects of the performed breast surgery and clinicopathological characteristics on surgical outcomes, LR rates and survival were analyzed with showing the distribution of <i>BRCA1</i> and <i>BRCA2</i> germline mutations.</p><p><strong>Results: </strong>The median age of the patients was 42 years (20-77). <i>BRCA1</i> mutations were found in 46 (61.3%) patients and <i>BRCA2</i> mutations in 29 (38.7%) patients. Compared to <i>BRCA2</i> carriers, <i>BRCA1</i> carriers were more likely to have higher tumor grade (84.8% vs 44.8%; <i>p</i> = 0.001) and non-luminal subtype tumors (67.4% vs 13.8%; <i>p</i> = 0.001). A total of 44 (58.7%) patients underwent unilateral mastectomy and 31 (41.3%) patients underwent BCS. At a median follow-up time of 60 (12-240) months, LR was observed in 6 patients equally divided in both BCS and mastectomy groups. LR rates were slightly higher after BCS versus mastectomy (9.7% and 6.8%, respectively). Additionally, there were no statistically significant differences in disease-free survival (DFS) and disease-specific survival (DSS) rates after 10 years in the BCS group versus the mastectomy group (<i>p</i> = 0.117 and 0.109, respectively), but in fact, the rates were better in the BCS group.</p><p><strong>Conclusion: </strong>Our findings indicate that BCS may serve as an efficacious alternative to mastectomy for breast cancer patients with <i>BRCA1</i> or <i>BRCA2</i> mutation. Additionally, tumor size, lymph node positivity, and TNM stage should be taken into consideration for a better surgical decision-making.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/85/bctt-15-163.PMC9960707.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S395054","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The optimal surgical therapy for newly diagnosed breast cancer with germline mutations in susceptibility genes is still uncertain for many physicians. In this study, we aimed to determine the efficacy of breast conserving surgery (BCS) in breast cancer patients with BRCA1 or BRCA2 mutation by assessing its outcomes and locoregional recurrence (LR) rates.

Materials and methods: Seventy-five patients operated with BCS or mastectomy for breast cancer between 2006 and 2017 and had BRCA1 or BRCA2 mutation were included in the study. Effects of the performed breast surgery and clinicopathological characteristics on surgical outcomes, LR rates and survival were analyzed with showing the distribution of BRCA1 and BRCA2 germline mutations.

Results: The median age of the patients was 42 years (20-77). BRCA1 mutations were found in 46 (61.3%) patients and BRCA2 mutations in 29 (38.7%) patients. Compared to BRCA2 carriers, BRCA1 carriers were more likely to have higher tumor grade (84.8% vs 44.8%; p = 0.001) and non-luminal subtype tumors (67.4% vs 13.8%; p = 0.001). A total of 44 (58.7%) patients underwent unilateral mastectomy and 31 (41.3%) patients underwent BCS. At a median follow-up time of 60 (12-240) months, LR was observed in 6 patients equally divided in both BCS and mastectomy groups. LR rates were slightly higher after BCS versus mastectomy (9.7% and 6.8%, respectively). Additionally, there were no statistically significant differences in disease-free survival (DFS) and disease-specific survival (DSS) rates after 10 years in the BCS group versus the mastectomy group (p = 0.117 and 0.109, respectively), but in fact, the rates were better in the BCS group.

Conclusion: Our findings indicate that BCS may serve as an efficacious alternative to mastectomy for breast cancer patients with BRCA1 or BRCA2 mutation. Additionally, tumor size, lymph node positivity, and TNM stage should be taken into consideration for a better surgical decision-making.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
保乳手术对BRCA1或BRCA2种系突变乳腺癌患者有效吗?
背景:对于新诊断的易感基因发生种系突变的乳腺癌,最佳的手术治疗方法对许多医生来说仍然不确定。在这项研究中,我们旨在通过评估保乳手术(BCS)的结果和局部复发率来确定保乳手术(BCS)对BRCA1或BRCA2突变乳腺癌患者的疗效。材料和方法:在2006年至2017年期间,75例BRCA1或BRCA2突变的乳腺癌患者接受了BCS或乳房切除术。分析了乳房手术和临床病理特征对手术结果、LR率和生存率的影响,并显示了BRCA1和BRCA2种系突变的分布。结果:患者中位年龄42岁(20 ~ 77岁)。46例(61.3%)患者发现BRCA1突变,29例(38.7%)患者发现BRCA2突变。与BRCA2携带者相比,BRCA1携带者更有可能具有更高的肿瘤分级(84.8% vs 44.8%;P = 0.001)和非腔内亚型肿瘤(67.4% vs 13.8%;P = 0.001)。44例(58.7%)患者行单侧乳房切除术,31例(41.3%)患者行BCS。中位随访时间为60(12-240)个月,平均分为BCS组和乳房切除术组的6例患者观察到LR。与乳房切除术相比,BCS后的LR率略高(分别为9.7%和6.8%)。此外,与乳房切除术组相比,BCS组10年后无病生存(DFS)和疾病特异性生存(DSS)率无统计学意义差异(p分别= 0.117和0.109),但事实上,BCS组的比率更好。结论:我们的研究结果表明,对于BRCA1或BRCA2突变的乳腺癌患者,BCS可能是乳房切除术的有效替代方法。此外,肿瘤大小、淋巴结阳性和TNM分期也应考虑在内,以便更好地做出手术决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
期刊最新文献
Hyperbaric oxygen treatment promotes tendon-bone interface healing in a rabbit model of rotator cuff tears. Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders. Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice. Heme oxygenase/carbon monoxide system and development of the heart. Hyperbaric oxygen for moderate-to-severe traumatic brain injury: outcomes 5-8 years after injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1